Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Updates from MURANO for CLL: time-limited VenR & impact of MRD

John Seymour • 3 Dec 2018
ASH 2018
Chronic Lymphocytic Leukemia Leukemia Rituximab Venetoclax
MURANO

John Seymour, MBBS, FRACP, PhD, of the Peter MacCallum Cancer Centre, East Melbourne, Australia, gives us the key updates from the MURANO study (NCT02005471) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. This included establishing a time-limited venetoclax-rituximab regimen for relapsed/refractory chronic lymphocytic leukemia (CLL), and the first prospective data on the impact of MRD on long-term outcomes after this therapy.

More from John Seymour

3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
2:18
Efficacy of subsequent therapies for CLL patients treated in the MURANO trial
John Seymour • 8 Dec 2023
3:54
CLL advances: What will we see more of in 2021?
John Seymour • 7 Dec 2020
8:04
The MURANO study in CLL: 5 years on
John Seymour • 7 Dec 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals